China Biologic Products Incorporated

Aegis Capital Corporation today initiated coverage of four Chinese biotech and biomedical firms that are expected to perform well in the near future. Aegis initiated a 15-month price target of $12 per share for TrovaGene (Nasdaq: TROV), which at the time of the report was only valued at $4.61 per...